How do you find a legal psychedelic therapist and what is currently available?

The legal landscape for psychedelic-assisted therapy is shifting rapidly, and the honest answer is that availability depends heavily on where you live, what substance is in question, and whether you are willing to work within clinical trial frameworks or licensed state programs. What follows is a map of the current terrain, with some depth-psychological context for why the legal container matters as much as the molecule.

What is currently legal in the United States

As of now, the clearest legal pathway in the United States is ketamine, which is FDA-approved as an anesthetic and, in its nasal-spray form (esketamine/Spravato), approved for treatment-resistant depression. Ketamine infusion clinics operate legally across the country; a psychiatrist or anesthesiologist can administer it in an outpatient setting. The quality of the therapeutic container varies enormously — some clinics offer little more than the infusion itself, while others integrate preparation and integration sessions with trained therapists.

Oregon became the first state to license psilocybin service centers under Measure 109, passed in 2020. Licensed facilitators began working with clients in 2023. This is not a medical model — you do not need a diagnosis — but it is a supervised, licensed framework. Colorado passed a similar measure in 2022, with a broader set of substances (psilocybin, psilocin, DMT, ibogaine, mescaline) and a rollout expected through 2025–2026. These state programs are the most accessible legal pathways for psilocybin work outside of clinical trials.

Clinical trials remain the other major avenue. Johns Hopkins, NYU, UCSF, and a number of other research institutions are actively enrolling participants for psilocybin and MDMA studies. MAPS (the Multidisciplinary Association for Psychedelic Studies) has been running Phase 3 trials for MDMA-assisted therapy for PTSD; the FDA rejected the application in 2024 and requested additional trials, so MDMA is not yet approved, but expanded access programs may be available for qualifying patients. ClinicalTrials.gov is the authoritative registry — searching "psilocybin" or "MDMA" there will show currently enrolling studies.

How to find a practitioner

For ketamine: the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3) maintains a directory. Look for providers who pair infusions with psychotherapy rather than offering the molecule alone.

For Oregon psilocybin: the Oregon Health Authority publishes a registry of licensed service centers and facilitators at psilocybinservices.oregon.gov.

For clinical trials: ClinicalTrials.gov, filtered by condition and location, is the most reliable source. Many trials cover costs for participants.

For integration support regardless of substance: the Multidisciplinary Association for Psychedelic Studies (MAPS) and the California Institute of Integral Studies (CIIS) have trained cohorts of therapists specifically in psychedelic integration. Therapists trained through these programs can legally provide preparation and integration work even where the substances themselves are not yet legal.

Why the container is not incidental

The depth-psychological literature is unambiguous on this point. Grof's decades of research established that the drug itself functions as a non-specific amplifier — what he called "set and setting" determines whether what emerges is therapeutic or destabilizing:

The drug itself is seen as a catalyst that activates the unconscious processes in a rather unspecific way. Whether the emergence of the unconscious material will be therapeutic or destructive is not determined simply by the biochemical and physiological action of LSD. It is a function of a number of non-drug variables, such as the personality structure of the subject, the relationship he or she has with the guide, sitter or persons present in the session, the nature and degree of specific psychological help, and the set and setting of the psychedelic experience.

Strassman arrived at the same conclusion from a different direction, writing that "the spirit molecule is neither good nor bad, beneficial nor harmful, in and of itself. Rather, set and setting establish the context and the quality of the experiences to which DMT leads us" (Strassman, 2001). The molecule opens a door; what you meet on the other side, and whether you can metabolize it, depends on the relational and psychological container you bring.

This is why the question of legality is inseparable from the question of quality. An underground guide may be skilled and experienced — Mahr (2020) notes that many such guides "are highly skilled, insightful, and experienced" and "do the work as a calling" — but the absence of legal accountability also means the absence of enforceable standards. The legal frameworks emerging in Oregon and Colorado are imperfect, but they create a minimum container: training requirements, ethical codes, and recourse if something goes wrong.

The practical recommendation: if you are in Oregon or Colorado, begin with the state registry. If you are elsewhere, look first at clinical trials for your condition, then at ketamine providers who integrate psychotherapy, then at therapists trained in psychedelic integration who can do the preparation and processing work regardless of what substance you eventually access and where.

  • Stanislav Grof — portrait of the psychiatrist whose decades of LSD research established the foundational framework for psychedelic-assisted therapy
  • Rick Strassman — portrait of the researcher behind the first FDA-approved human DMT studies
  • Active imagination — the Jungian practice most closely analogous to the guided psychedelic experience
  • Find a depth-oriented therapist — curated directory of Jungian and depth-psychology practitioners

Sources Cited

  • Grof, Stanislav, 1980, LSD Psychotherapy: Exploring the Frontiers of the Hidden Mind
  • Strassman, Rick, 2001, DMT: The Spirit Molecule
  • Mahr, Greg, 2020, Psychedelic Drugs and Jungian Therapy